Farrah Kheradmand, MD, explains the effects of vaping duration on lung function.
When mice were exposed to 3 months of electronic cigarettes, and then exposed them to influenza, these mice succumbed to influenza much faster, said Farrah Kheradmand, MD, a professor of medicine-pulmonary at Baylor College of Medicine and a staff physician at the Houston Veterans Affairs (VA) medical center. Kheradmand's research was presented at this year's American Thoracic Society (ATS) 2021 virtual conference.
Transcript:
Based on your research, would you expect to see differential outcomes based on time of use, or repeated use of vapes?
Yes, and that's exactly what we found. We found that as early as a month, if you take these alveolar macrophages and put them in culture, and then try to simulate a scenario where they actually need to activate some markers, some genes, and some proteins, in order to combat a virus, they're not doing that. They're not doing a normal function as early as a month. Now, when we then took these mice and exposed them to 3 months of electronic cigarette, and then exposed them, in real life, to influenza these mice succumbed to influenza much faster and lost a lot more weight, and they were much, much sicker, again, independent of nicotine, than mice that were exposed to air.
What are the next steps for your research?
Yes, so lots of interesting questions fall out of that. One of the missions of my lab is to try to crack this story further open so we could see that if we get patients with electronic induced vaping and electronic-associated lung injury, how can we help them? How can we go back and now reverse the pathology? We have some ideas; we have some molecules in mind. We know that the macrophages display very different cell surface markers, and we're trying to understand what makes the sulfur surface markers different. We’re basically pursuing lots of different mediators that correlate with the changes and we're going to functionally change them or re-expose them to the some of these missing factors to see if that can reverse the process.
Semaglutide Eligibility Expands to Over Half of US Adults
November 21st 2024Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Read More
Community Investment, Engagement Are Essential to Fully Address Cardiovascular Health Disparities
November 19th 2024Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen